NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis $2.85 -0.04 (-1.38%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.85 +0.00 (+0.07%) As of 10/9/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NRx Pharmaceuticals Stock (NASDAQ:NRXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NRx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.82▼$2.8950-Day Range$2.85▼$3.6752-Week Range$1.62▼$5.05Volume289,297 shsAverage Volume699,710 shsMarket Capitalization$123.41 millionP/E RatioN/ADividend YieldN/APrice Target$34.50Consensus RatingHold Company Overview NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company’s programs are investigational and are intended to address areas where available therapies may have limitations. NRx’s lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior. The company has also evaluated ketamine-based therapies, including NRX-100, and has pursued ZYESAMI (aviptadil), an investigational treatment for respiratory failure associated with critical COVID-19. Regulatory approval and commercial availability may vary by product and indication. The company traces its origins to NeuroRx, which combined with Big Rock Partners Acquisition Corp. in 2021 in a transaction that resulted in the public company now known as NRx Pharmaceuticals. Its development activities have primarily centered on clinical research and regulatory programs in the United States, with studies and collaborations involving international locations. NRx is led by founder Jonathan Javitt, who has served in senior executive and scientific roles at the company.AI Generated. May Contain Errors. Read More NRx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreNRXP MarketRank™: NRx Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 651st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingNRx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialNRx Pharmaceuticals has a consensus price target of $34.50, representing about 1,110.5% upside from its current price of $2.85.Amount of Analyst CoverageNRx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NRx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($0.80) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.17% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 13.98, which indicates bearish sentiment.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 0.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.28 News SentimentNRx Pharmaceuticals has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for NRx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for NRXP on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat Follows6 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.40% of the stock of NRx Pharmaceuticals is held by insiders.Percentage Held by Institutions4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRXP Stock News HeadlinesQ3 EPS Estimate for NRx Pharmaceuticals Lowered by AnalystOctober 6, 2026 | americanbankingnews.comNRx (NASDAQ: NRXP) secures DARPA contract for depression trial and $11.2 million awardOctober 6, 2026 | americanbankingnews.comWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.October 10 at 1:00 AM | Stansberry Research (Ad)Astrazeneca (NYSE:AZN) & NRx Pharmaceuticals (NASDAQ:NRXP) Head to Head ReviewOctober 5, 2026 | americanbankingnews.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Stock Rated "Hold" by Sell-Side BrokeragesOctober 4, 2026 | americanbankingnews.comReviewing NRx Pharmaceuticals (NASDAQ:NRXP) and Elanco Animal Health (NYSE:ELAN)October 1, 2026 | americanbankingnews.comNRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for ...September 30, 2026 | markets.businessinsider.comNRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant DepressionSeptember 30, 2026 | globenewswire.comSee More Headlines NRXP Stock Analysis - Frequently Asked Questions How have NRXP shares performed this year? NRx Pharmaceuticals' stock was trading at $2.71 at the start of the year. Since then, NRXP stock has increased by 5.2% and is now trading at $2.85. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) posted its quarterly earnings results on Friday, August, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.33. The firm earned $1.10 million during the quarter, compared to analyst estimates of $1.33 million. Read the conference call transcript. When did NRx Pharmaceuticals' stock split? NRx Pharmaceuticals shares reverse split before market open on Tuesday, April 2nd 2024.The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NRx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), GE Aerospace (GE) and Disc Medicine (IRON). Company Calendar Last Earnings8/14/2026Today10/10/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NRXP's financial health is in the Green zone, according to TradeSmith. NRXP has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NRXP CIK1719406 Webnrxpharma.com Phone(484) 254-6134FaxN/AEmployees29Year Founded2015Price Target and Rating Average Price Target for NRx Pharmaceuticals$34.50 High Price Target$49.00 Low Price Target$10.00 Potential Upside/Downside+1,110.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.62 million Net Margins-691.81% Pretax Margin-692.13% Return on EquityN/A Return on Assets-63.92% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual Sales$1.23 million Price / Sales100.33 Cash FlowN/A Price / Cash FlowN/A Book Value($0.54) per share Price / Book-5.28Miscellaneous Outstanding Shares43,300,000Free Float40,525,000Market Cap$123.41 million OptionableOptionable Beta2.07 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NRXP) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersTHE NEXT GREAT FINANCIAL CRISIS (it’s already here)Weiss Ratings was the only independent firm to warn before the 2008 Financial Crisis. Now it is sounding the a...Weiss Ratings | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
